Long-term safety of first-line osimertinib plus platinum-pemetrexed in EGFR-mutated advanced NSCLC: FLAURA2.
Long-term safety data confirm that combining chemotherapy with a targeted lung cancer drug is tolerable over extended treatment, supporting this as standard care.
This report presents extended long-term safety follow-up from the Phase III FLAURA2 trial, confirming sustained tolerability of the first-line osimertinib-chemotherapy combination that improved progression-free survival versus osimertinib monotherapy in EGFR-mutated NSCLC. The data resolve key uncertainty about cumulative toxicity with the combination regimen, supporting its implementation as a standard first-line option for eligible patients.
What the study was
- Study design
- Long-term safety follow-up from Phase III RCT (FLAURA2)
- Population
- EGFR-mutated advanced NSCLC patients eligible for first-line therapy
- Category
- Treatment Innovation
- Maturity
- Potentially Practice-Changing
- Journal
- Lung cancer (Amsterdam, Netherlands)
Why it surfaced
Long-term safety confirmation for the FLAURA2 regimen—a Phase III-validated first-line combination in EGFR NSCLC; resolves critical safety uncertainty for adoption of a practice-changing combination.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.